ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ソタロール

Sotalol

HCID 5253
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
3930-20-9
標準SMILES
CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1
InChIKey
ZBMZVLHSJCTVON-UHFFFAOYSA-N
分子式
C12H20N2O3S
平均分子量
272.37 g/mol
単同位体質量
272.11946368

概要

Sotalol is a sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias. It has a role as a beta-adrenergic antagonist, a xenobiotic, an anti-arrhythmia drug and an environmental contaminant. It is a member of ethanolamines, a sulfonamide, a secondary alcohol and a secondary amino compound. It is a conjugate base of a sotalol(1+).

名称と識別子

優先名称
Sotalol
IUPAC
N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide
現地名
ソタロール
英語名
Sotalol
分子式
C12H20N2O3S
分子量
272.36

名称と別名

sotalol3930-20-9beta-CardoneDL-SotalolSotalolumDarob miteDTXSID00235894'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilideMethanesulfonanilide, 4'-(1-hydroxy-2-(isopropylamino)ethyl)-C07AA07A6D97U294IN-(4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}phenyl)methanesulfonamide
名称をさらに表示
d-ソタロール(+)-ソタロールN-[4-[(S)-1-ヒドロキシ-2-[(1-メチルエチル)アミノ]エチル]フェニル]メタンスルホンアミドN-[4-[1-ヒドロキシ-2-(イソプロピルアミノ)エチル]フェニル]メタンスルホンアミド(R)-ソタロール(αS)-4-[(メチルスルホニル)アミノ]-α-[(イソプロピルアミノ)メチル]ベンゼンメタノール(-)-ソタロール(S)-ソタロールN-[4-[2-(イソプロピルアミノ)-1-ヒドロキシエチル]フェニル]メタンスルホンアミドN-[4-[(R)-1-ヒドロキシ-2-[(1-メチルエチル)アミノ]エチル]フェニル]メタンスルホンアミドl-ソタロールN-(4-{1-ヒドロキシ-2-[(プロパン-2-イル)アミノ]エチル}フェニル)メタンスルホンアミドソタロールSORBITOLSotalol (base and/or unspecified salts)SotololBetacotdoneAURORA KA-855Sotalol USP/EP/BPSotalol Intermediate
Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-DTXCID303589CHEBI:63622Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]-SotaloloN-(4-(1-hydroxy-2-((propan-2-yl)amino)ethyl)phenyl)methanesulfonamideRefChem:56607MJ1999

物性

構造計算による物性

XLogP
0.2
極性表面積
86.8 Ų
水素結合供与体数
3
水素結合受容体数
5
回転可能結合数
6
重原子数
18
形式電荷
0
複雑度
330

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals

Pharmaceuticals -> Used in Switzerland

LogP · 2 件

1.1

0.53

Solubility7.82e-01 g/L
Human Drugs · 2 件

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Adrenergic Beta-Antagonists; Antiarrhythmics

Pharmaceuticals

Melting Point206.5 - 207 °C
Physical DescriptionSolid
Dissociation Constants9.76
Collision Cross Section167 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

物理化学的性質

融点
206.5 · 206.5-207 °C
沸点
443.3 · 443.3±55.0 °C(Predicted)
比重(密度)
1.298 g/cm3 · 1.298 g/cm3

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P203, P260, P263, P264, P264+P265, P270, P280, P302+P352, P305+P351+P338, P318, P319, P321, P332+P317, P337+P317, P362+P364, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

危険有害性情報

Hazard Classes and CategoriesSkin Irrit. 2 (100%)

毒性情報

Hepatotoxicity · 1 件

Mild-to-moderate elevations in serum aminotransferase levels occur in less than 2% of patients on sotalol and are usually transient and asymptomatic, resolving even with continuation of therapy. Sotalol has been linked to a single case of clinically apparent liver injury, with onset of an acute hepatitis-like syndrome with prolonged jaundice 12 weeks after sotalol was initiated. The injury improved but did not resolve with discontinuation of sotalol. In large case series of drug induced liver disease and acute liver failure, sotalol has not been listed as a cause. Other beta-blockers have been linked to rare instances of acute clinically apparent liver injury with a latency to onset ranging from 4 to 24 weeks, a hepatocellular pattern of serum enzyme elevations and a mild, self-limiting course without evidence of hypersensitivity or autoimmune reactions.

Adverse Effects · 1 件

Sotalol's adverse effect profile is inherent in the mechanisms of action as both a potassium channel blocker and a non-cardioselective β-blocker. The potassium channel blockade, primarily in phase 3 of the cardiac action potential, prolongs the QTc. Thus, the electrocardiogram (ECG) must be monitored upon initiating sotalol or adding other QTc-prolonging medications. Prolongation of the QT interval occurs in 1% to 2% of cases, which could lead to torsades de pointes or new ventricular tachycardia/ventricular fibrillation.

化学と産業

薬理情報

ATC Code · 3 件

C07AA07

C - Cardiovascular system

QC - Cardiovascular system

Protein Binding0%.
Pharmacodynamics · 1 件

Sotalol is a competitive inhibitor of the rapid potassium channel. This inhibition lengthens the duration of action potentials and the refractory period in the atria and ventricles. The inhibition of rapid potassium channels is increases as heart rate decreases, which is why adverse effects like torsades de points is more likely to be seen at lower heart rates. L-sotalol also has beta adrenergic receptor blocking activity seen above plasma concentrations of 800ng/L. The beta blocking ability of sotalol further prolongs action potentials. D-sotalol does not have beta blocking activity but also reduces a patient's heart rate while standing or exercising. These actions combine to produce a negative inotropic effect that reduces the strength of contractility of muscle cells in the heart. Extension of the QT interval is also adversely associated with the induction of arrhythmia in patients. Hyperglycemia is a greater risk for non insulin dependant diabetics than insulin dependant diabetics. Beta blockers inhibit insulin secretion which may cause hyperglycemia in type II diabetes mellitus. The risk of hypoglycemia is higher in insulin dependant diabetes than non insulin dependant diabetics. Beta blockers decrease secretion of insulin, which may mask hypoglycemia in an insulin dependant patient. Beta blockers also increase glucose uptake into cells which may prolong or potentiate hypoglycemia. Further information regarding adverse reactions can be found here.

Mechanism of Action · 1 件

Sotalol inhibits beta-1 adrenoceptors in the myocardium as well as rapid potassium channels to slow repolarization, lengthen the QT interval, and slow and shorten conduction of action potentials through the atria. The action of sotalol on beta adrenergic receptors lengthens the sinus node cycle, conduction time through the atrioventricular node, refractory period, and duration of action potentials.

Biological Half-Life · 1 件

The terminal elimination half life is 10-20 hours in healthy patients. In patients with a creatinine clearance >80mL/min, the half life is 17.5±0.97h. In patients with a creatinine clearance 30-80mL/min, the half life is 22.7±6.4h. In patients with a creatinine clearance 10-30mL/min, the half life is 64±27.2h. In patients with a creatinine clearance <10mL/min, the half life is 97.9±57.3h.

関連反応

5 件
反応記録を作成
HRID 479264 の反応式
HRID 479264生成物として
HRID 651495 の反応式
HRID 651495生成物として
HRID 651496 の反応式
HRID 651496生成物として
HRID 1534563 の反応式
HRID 1534563生成物として
HRID 2301241 の反応式
HRID 2301241生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
3930-20-9
PubChem CID
5253
DTXSID
DTXSID0023589
ChEMBL
CHEMBL471
ChEBI
CHEBI:63622
UNII
A6D97U294I
EC Number
977-025-7
Nikkaji
J10.583J
貯蔵温度
-20 °C · Hygroscopic, -20°C Freezer, Under inert atmosphere
溶解性
クロロホルム(わずかに、加熱)、メタノール(わずかに、超音波処理)
外見
個体
酸解離定数(Pka)
1 · pK1 8.2, pK2 9.8(at 25℃)
色
淡黄色~淡黄色
BCS Class
1 · 1
安定性
Hygroscopic
InChI
InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3
InChIKey
ZBMZVLHSJCTVON-UHFFFAOYSA-N
SMILES
CS(NC1=CC=C(C(O)CNC(C)C)C=C1)(=O)=O
CAS データベース
3930 · 3930-20-9(CAS DataBase Reference)
NISTの化学物質情報
4 · Methanesulfonanilide, 4'-(1-hydroxy-2-(isopropylamino)ethyl)-(3930-20-9)
EPAの化学物質情報
4 · Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]- (3930-20-9)
Toxicity Summary · 1 件

Sotalol toxicity is inherent due to the mechanism of action as both a potassium channel blocker and a non-cardioselective β-blocker and mirrors the adverse effect profile. The most obvious and potentially problematic sign of toxicity is concentration-related QTc prolongation. If QTc is over 500 ms during initiation, the sotalol dose should be reduced or discontinued. If QTc exceeds 520 ms during the maintenance phase of dosing, the clinician should either reduce the dose or discontinue sotalol.

Drug Induced Liver Injury · 5 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

sotalol

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
EPA Human Health Benchmarks for Pharmaceuticals · 6 件

Sotalol

1.9

7.9

The starting dose of sotalol hydrochloride tablets (AF) is 80 mg twice daily (b.i.d.) if the creatinine clearance is > 60 mL/min, and 80 mg once daily (q.d.) or 40 mg twice daily (b.i.d) if the creatinine clearance is 40 to 60 mL/min.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 80 mg/day, Lowest Therapeutic Dose (LTD): 1.0 mg/kg-day, and Screening Dose: 0.0003 mg/kg-day.

22-Jan-07

安全データ

risk_code
36/37/38
hazard_code
Xi
safety_code
26-36
Metabolism/MetabolitesSotalol is not metabolized.
FDA Pharmacological Classification · 6 件

A6D97U294I

SOTALOL

Established Pharmacologic Class [EPC] - Antiarrhythmic

Physiologic Effects [PE] - Cardiac Rhythm Alteration

Mechanisms of Action [MoA] - Adrenergic beta-Antagonists

Sotalol is an Antiarrhythmic. The mechanism of action of sotalol is as an Adrenergic beta-Antagonist. The physiologic effect of sotalol is by means of Cardiac Rhythm Alteration.

MeSH Pharmacological Classification · 3 件

Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.

Absorption, Distribution and Excretion · 4 件

Sotalol is 90-100% bioavailable. When taken with a meal, adsorption is lowered by 18%. In patients with a creatinine clearance >80mL/min, the maximum concentration is 6.25±2.19.

80-90% of a given dose is excreted in the urine as unchanged sotalol. A small fraction of the doses is excreted in the feces as unchanged sotalol.

The apparent volume of distribution is 1.2-2.4L/kg.

In patients with a creatinine clearance >80mL/min, the plasma clearance is 6.78±2.72L/h and the renal clearance is 4.99±1.43L/h. In patients with a creatinine clearance 30-80mL/min, the plasma clearance is 2.74±0.53L/h and the renal clearance is 2.00±0.67L/h. In patients with a creatinine clearance 10-30mL/min, the plasma clearance is 1.56±0.44L/h and the renal clearance is 0.65±0.31L/h. In patients with a creatinine clearance <10mL/min, the plasma clearance is 0.65±0.20L/h and the renal clearance is 0.27±0.13L/h.

Cellular LocationsMembrane
Metabolite PathwaysSotalol Action Pathway

用途と製造

UsesUse (kg) in Switzerland (2009): >250
Use ClassificationPharmaceuticals
応用分野 · 1 件

一般的な説明Sotalol, 4'[1-hydroxy-2-(isopropylamino)ethyl]methylsulfonanilide (Betapace), is a relatively new antiarrhythmicdrug, characterized most often as a class IIIagent, and although it has effects that are related to the classII agents, it is not therapeutically considered a class II antiarrhythmic.It contains a chiral center and is marketed as theracemic mixture. Because of its enantiomers, its mechanismof action spans two of the antiarrhythmic drug classes. Thel(-) enantiomer has both β-blocking (class II) and potassiumchannel-blocking (class III) activities. The d(+) enantiomerhas class III properties similar to those of the (-) isomer,but its affinity for the -adrenergic receptor is 30 to 60 timeslower.

上流・下流製品情報

上流原料

塩酸
補足説明 · 1 件

定義ChEBI: A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is sustituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and ardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.